Penumbra, Inc.
PEN
Rang in aandelen
#1681
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Aandeelprijs
$323.27
Marktkapitalisatie
$12.73B
Verandering (1 dag)
0.15%
Verandering (1 jaar)
30.55%
Land
US
Handel Penumbra, Inc. (PEN)
Categorie
Healthcare
Winst voor Penumbra, Inc. (PEN)
Winst in Jun 2026 TTM: $203.83M
Volgens de meest recente financiële verslagen van Penumbra, Inc. bedraagt de huidige winst van het bedrijf $203.83M. In 2023 behaalde het bedrijf een winst van $79.65M, een stijging ten opzichte van de winst van 2022, die $3.89M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Penumbra, Inc. van 2012 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $203.83M | 876.72% |
| 2024 | $20.87M | -73.80% |
| 2023 | $79.65M | 1,946.51% |
| 2022 | $3.89M | -137.06% |
| 2021 | $-10.50M | -72.38% |
| 2020 | $-38.02M | -175.83% |
| 2019 | $50.14M | 3,017.85% |
| 2018 | $1.61M | -35.06% |
| 2017 | $2.48M | -384.93% |
| 2016 | $-869.00K | -121.60% |
| 2015 | $4.02M | 28.19% |
| 2014 | $3.14M | -350.12% |
| 2013 | $-1.26M | -132.25% |
| 2012 | $3.89M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $7.51B | 3,584.90% |
US
|
|
| $5.56B | 2,629.21% |
IE
|
|
| $5.15B | 2,425.61% |
US
|
|
| $3.86B | 1,794.21% |
US
|
|
| - | - |
DE
|
